Analyst Ratings for [TSHA] Taysha Gene Therapies Inc

7/11/25	Initiated	Buy	X
TSHA Taysha Gene Therapies BofA Securities
$8
6/27/24	Initiated	Outperform	X
TSHA Taysha Gene Therapies BMO Capital Markets
$5
4/9/24	Initiated	Overweight	X
TSHA Taysha Gene Therapies Piper Sandler
$9
2/1/23	Downgrades	Buy Hold	X
TSHA Taysha Gene Therapies Jefferies
$14 $1.50
1/27/23	Downgrades	Overweight Eq-Weight	X
TSHA Taysha Gene Therapies Morgan Stanley
$23 $3
11/9/22	Downgrades	Buy Neutral	X
TSHA Taysha Gene Therapies Goldman
$16 $3
3/9/22	Initiated	Outperform	X
TSHA Taysha Gene Therapies Robert W. Baird
$26
12/16/21	Initiated	Buy	X
TSHA Taysha Gene Therapies Guggenheim
$28
7/16/21	Initiated	Buy	X
TSHA Taysha Gene Therapies Needham
$45
6/24/21	Initiated	Buy	X
TSHA Taysha Gene Therapies Truist
$60
6/15/21	Initiated	Buy	X
TSHA Taysha Gene Therapies BTIG Research
$44
6/9/21	Initiated	Outperform	X
TSHA Taysha Gene Therapies Wedbush
$31
6/8/21	Initiated	Mkt Outperform	X
TSHA Taysha Gene Therapies JMP Securities
$40
5/19/21	Initiated	Overweight	X
TSHA Taysha Gene Therapies Cantor Fitzgerald
$44
5/11/21	Resumed	Buy	X
TSHA Taysha Gene Therapies Jefferies
$34 $45
2/24/21	Initiated	Outperform	X
TSHA Taysha Gene Therapies William Blair
1/5/21	Initiated	Outperform	X
TSHA Taysha Gene Therapies Oppenheimer
$42

TSHA Taysha Gene Therapies Inc

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Taysha Gene Therapies, Inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; TSHA-102 for the treatment of Rett syndrome; TSHA-103 for the treatment of SLC6A1 haploinsufficiency disorder; and TSHA-104 for the treatment for Surfeit locus 1 deficiency. The company also has strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. Taysha Gene Therapies, Inc. was founded in 2019 and is based in Dallas, Texas.